Nuvation Bio Inc. (NUVB)
| Market Cap | 1.85B +136.9% |
| Revenue (ttm) | 143.05M +1,205.5% |
| Net Income | -145.99M |
| EPS | -0.42 |
| Shares Out | 348.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,889,566 |
| Open | 4.76 |
| Previous Close | 4.72 |
| Day's Range | 4.72 - 5.38 |
| 52-Week Range | 1.57 - 9.75 |
| Beta | 1.52 |
| Analysts | Strong Buy |
| Price Target | 12.33 (+131.55%) |
| Earnings Date | May 4, 2026 |
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headqua... [Read more]
Financial Performance
In 2025, Nuvation Bio's revenue was $62.90 million, an increase of 698.96% compared to the previous year's $7.87 million. Losses were -$204.63 million, -63.97% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price target is $12.33, which is an increase of 131.55% from the latest price.
News
Nuvation Bio Transcript: Jefferies Global Healthcare Conference 2026
IBTROZI dominates the ROS1 lung cancer market with unmatched efficacy, long response duration, and strong CNS benefits, backed by guideline changes and patient-reported outcomes. Safusidenib advances in all IDH1 glioma subgroups, with promising results and new studies. The company maintains strong finances and disciplined business development.
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hun...
Nuvation Bio’s Ibtrozi shows improved quality of life in NSCLC trial
Nuvation Bio (NUVB) announced new patient-reported outcomes data from the pivotal TRUST-II study of Ibtrozi – taletrectinib – in patients with advanced ROS1-positive non-small cell lung cancer, or NSC...
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatment Cognitive function scores improved or remained ...
Nuvation Bio Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
IBTROZI is experiencing robust first-line growth and is expected to meet or exceed consensus targets, driven by strong efficacy and increasing physician adoption. Pipeline assets like safusidenib are advancing in underserved glioma populations, with key data expected next year.
Nuvation Bio Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by a strong quorum. No questions were raised, and voting results will be filed with the SEC within four business days.
Nuvation Bio Transcript: RBC Capital Markets Global Healthcare Conference 2026
IBTROZI drives strong revenue growth via increased first-line patient share, enhanced testing, and superior efficacy. New guidelines and state mandates expand the market. Safusidenib shows superior efficacy in glioma, with pivotal trials underway and large commercial potential. The company is well-capitalized to advance its pipeline and pursue disciplined business development.
Nuvation Bio Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
IBTROZI leads the ROS1 NSCLC market with best-in-class efficacy, expanding into the adjuvant setting and driving strong revenue growth. Safusidenib shows superior results in IDH1 gliomas, with pivotal trial readouts ahead. A new DDC program update is expected later this year.
Nuvation Bio collaborating with Thermo Fisher to manufacture Ibtrozi in NSCLC
Nuvation Bio (NUVB) announced the completion of process tech transfer and product introduction to Thermo Fisher (TMO) for Ibtrozi – taletrectinib – to treat advanced or metastatic ROS1-positive non-sm...
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
Thermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for Nuvation Bio in the United States Move by Nuvation Bio further ensures critical drug supply for pat...
Nuvation Bio Transcript: Bank of America Global Healthcare Conference 2026
ZUSDURI's launch is exceeding expectations with rapid revenue growth, strong community adoption, and durable clinical benefit. Pipeline assets are advancing, including next-gen mitomycin and an oncolytic virus, supporting ambitions to expand beyond urothelial cancers.
Nuvation Bio: FDA accepts sNDA with updated data for IBTROZI
Nuvation Bio (NUVB) announced that the U.S. FDA has accepted a supplemental New Drug Application with updated data for IBTROZI in both TKI-naive and TKI-pretreated advanced ROS1-positive non-small cel...
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
Application includes updated TRUST-I TKI-naïve median duration of response (mDOR) and median progression-free survival (mPFS) of more than 4 years, as well as TRUST-II TKI-pretreated mDOR of nearly 20...
Nuvation Bio to Participate in Upcoming Investor Conferences
NEW YORK, May 5, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung...
Nuvation Bio Earnings Call Transcript: Q1 2026
Strong Q1 2026 results driven by Ibtrozi's expanding first-line use, robust revenue growth, and broad adoption across U.S. and international markets. Safusidenib program advanced with global rights secured and pivotal trial expansion.
Nuvation Bio Quarterly report: Q1 2026
Nuvation Bio has published its Q1 2026 quarterly earnings report on May 4, 2026.
Nuvation Bio Earnings release: Q1 2026
Nuvation Bio released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Nuvation Bio reports Q1 EPS 1c, consensus 5c
Reports Q1 revenue $83.23M, consensus $62.34M. “We are pleased with IBTROZI’s ongoing launch trends in the first quarter of 2026, as we continue to deepen its adoption across lines of…
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI ® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in the first quarter of 2026 were TKI-...
Nuvation Bio Slides: Investor presentation
Nuvation Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastases NEW YORK, April 27, 2026 /PRNewswire/ -- N...
Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI
Nuvation Bio (NUVB) announced results from a pooled analysis of long-term follow-up data from the pivotal TRUST-I and TRUST-II trials for IBTROZI, or taletrectinib, in patients with advanced ROS1-posi...
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in TKI-naïve patients IBTROZI a...
Nuvation Bio Proxy statement: Proxy filing
Nuvation Bio filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Nuvation Bio Slides: Corporate presentation
Nuvation Bio has posted slides in relation to its latest quarterly earnings report, which was published on April 21, 2026.